Valsartan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and SMC (Scotland) recommended or restricted valsartan, while AWMSG (Wales), CIPM (Spain) and PHARMAC (New Zealand) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “Treatment of hypertension in children and adolescents 6 to 18”, while AWMSG (Wales) recorded not recommended for “Treatment of hypertension in children and adolescents 6 to 18 years of age”.
The file has been open for more than a decade: 21.6 years separate the first record, 22 May 2003 at PHARMAC (New Zealand), from the most recent, 18 Dec 2024 at CIPM (Spain).
SMC (Scotland) changed its position: recommended on 11 Feb 2008, restricted by 17 Jan 2011.
No assessment is on file from PBAC (Australia), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for valsartan by the agencies that label one in English (AWMSG and SMC).
PHARMAC (New Zealand) was first to assess valsartan, on 22 May 2003; CIPM (Spain) did not open a file until 18 Dec 2024 — an unusually long tail of 21.6 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 8 years in total.
3 of the 5 agencies here assessed valsartan more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed valsartan.
The full ledger for valsartan reads 9 other, 4 not recommended, 4 recommended and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 18 Dec 2024 | Indicación terapéutica autorizada: Valomindo está indicado para el tratamiento de la hipertensión esencial como terapia … | not financed by the SNS · art. 92 d | source |
| HAS (France) | 22 Apr 2020 | Indication extension | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 31 Mar 2011 | Treatment of hypertension in children and adolescents 6 to 18 years of age | not recommended (limited) | source |
| SMC (Scotland) | 17 Jan 2011 | Treatment of hypertension in children and adolescents 6 to 18 | accepted (restricted) | source |
| PHARMAC (New Zealand) | 22 May 2003 | Hypertension and CHF | PTAC advice: Decline · decision reached | source |
13 further decisions for valsartan, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- candesartan — same ATC class C09C — Renin-angiotensin system
- sacubitril / valsartan — same ATC class C09C — Renin-angiotensin system
- losartan — same ATC class C09C — Renin-angiotensin system
- olmesartan — same ATC class C09C — Renin-angiotensin system
- telmisartan — same ATC class C09C — Renin-angiotensin system
- gadopiclenol — also decided by CIPM in 2024Q4
Coverage: 18 decisions for valsartan from 5 agencies, 2003 to 2024. Data to 7 Sep 2026. ATC class C09C — Renin-angiotensin system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.